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Hematopoietic tuberculosisAbstract Hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially a fatal disease. It is
either primary or secondary and it is linked to various etiologies. Its therapeutic management is
always difficult and not codified in the absence of large-scale controlled studies. We report a case
of secondary HLH associated with hematopoietic tuberculosis in an immunocompetent adult.
 2015 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a rare but
potentially a fatal disease. It is either primary or secondary
and it is linked to various etiologies. To be originated from
tuberculosis is exceptional. Its therapeutic management is not
codified. We report a case of HLH associated with tuberculosis.
Observation
A 34 year old patient was treated for lymphatic tuberculosis
7 years ago by isoniazid, pyrazinamide, ethambutol and rifam-
picin for 2 months, followed by isoniazid and rifampicin for
4 months. He had fever, night sweats, anorexia and weight loss
of 15 kg. Clinical examination revealed a cachectic patient,
fever at 38.5 C and hypotension at 85 mmHg/65 mmHg.Abdominal examination shows an isolated hepatosplenome-
galia. The CBC showed a normochromic normocytic anemia
at 5.6 g/dl, a leukoneutropenia at 1000/mm3 and thrombocy-
topenia at 50,000/mm3. CRP increased to 220 mg/L and liver
function is disrupted with a cytolysis at more than 5 times
the normal and anicteric cholestasis. Prothrombin time was
60%. Blood cultures and cytobacteriological urinalysis came
back negative. The standard chest X-ray was normal. The tho-
racoabdominal CT scans showed an isolated homogeneous
hepatosplenomegaly. The diagnosis of HLH was suspected.
The Ferritin increased to 6279 lg/L. The hypertriglyceridemia
was at 5 g/L. The LDH was slightly raised to 432 UI/L. HIV
and hepatitis B and C serologies were negative as well as the
acid-alcohol resistant bacillus research in sputum and urine.
The smears and thick blood films excluded a blood parasitosis.
The bone marrow aspiration was found normally rich
marrow with significant histiocytosis which was in favor of
hemophagocytic syndrome. The mye´loculture is not
performed. The marrow biopsy showed hemophagocytosis
associated with disseminated medullary granulomas
epithelioid-giant cell with caseous necrosis. The diagnosis of
HLH secondary to hematopoietic tuberculosis was
retained. The patient was put under antituberculosis therapy
366 N. Zemed et al.(streptomycin, ethambutol, pyrazinamide, isoniazid and
rifampicin) and oral corticoid (prednisolone 1 mg/kg/day). The
patient died three weeks after admission.
Discussion
The HLH is a clinicopathological entity characterized by
increased stimulation and proliferation of benign macrophages
responsible for abnormal hemophagocytosis [1]. Several names
are used to indicate the entity [1,2]. The HLH is a rare disease
that primarily affects children especially for primary forms but
can appear at any age. It is probably underestimated with an
incidence of 0.6 to 1 cases/500,000 inhabitants. Only 2197 cases
were reported between 1975 and 2011. Approximately 50% of
cases are reported in Japan [3]. The pathophysiological
hypothesis suggests stimulatory cytokine secretion by CD8 T
cells and activated natural killer (NK) cells, which lost their
cytotoxic power, responsible for an abnormal activation of
macrophages causing hypersecretion of pro-inflammatory
cytokines including Tumor Necrosis Factor alpha (TNF),
gamma interferon and interleukins [3]. At least five genetic
autosomal recessive deficits are identified in primary forms
and two others are linked to the X chromosome [4]. There is
primary and secondary forms. The causes of secondary form
are dominated by infection (50.4%). Bacterial infections are
reported in 9% of cases of which 38% are due to tuberculosis
[3].
HLH related to tuberculosis in 36 patients were listed in a
literature review, characterized by the presence of the underly-
ing comorbidities and the predominance of extra-thoracic
tuberculosis [5]. The diagnosis of secondary HLH is retained
in front of the combination of clinical, laboratory and
histopathological signs. The clinical picture is nonspecific
[3,6]. Coagulation abnormalities are secondary to the disrup-
tion of liver function. The hyperferritinemia can be explained
by the secretion of ferritin by macrophages or hepatocytes,
or its release during erythrophagocytosis. Elevated LDH is sec-
ondary to cell destruction. Hyponatremia may be associated
with the inappropriate secretion anti-diuretic hormone syn-
drome. Hypertriglyceridemia is secondary to an inhibition of
lipoprotein lipase by TNF [3]. Some serological tests can mea-
sure the abnormal immunological response. Markers of
macrophage activation and cytokines are high during the
HLH [3]. However, the key immunological markers are the
high rate of CD25 and CD163 and the reduced or absent cel-
lular activity of NK. However, these tests are rarely available
in specialized centers. Bone marrow aspiration has a sensitivity
of 84% for the diagnosis of HLH [7]. It shows rich marrow
infiltration by histiocytosis of a benign cytological appearance.
The medullary macrophages show intracytoplasmic vacuoles
containing blood cellular elements or their hematopoietic pre-
cursors. The erythroblastosis is frequently observed. Most
studies require a number of macrophage showing signs of
phagocytic activity above 2–3% and a median of 6 histiocyto-
sis per 500 nucleated cells [3]. The bone marrow biopsy is
barely contributory but it may reveal hemophagocytosis with
macrophage proliferation. It remains useful for the etiological
diagnosis of the underlying hematological disease. The Phago-
cytosis may not be present initially and a second biopsy may be
indicated in case of strong suspicion of HLH. Other cytologi-
cal and histological tests may be informative [7]. In youngadults, genetic testing has a double interest: in some situations
that suggest primary form of late-onset [3] and in ‘‘secondary”
HLH that may occur in patients with mutations or genetic
polymorphisms susceptibility. The ‘‘Histiocyte Society” was a
prospective registry of cases of HLH to identify diagnostic cri-
teria or ‘‘Henter criteria”. They were published for the first
time in 1991, revised in 1994 and new criteria were added in
2004 [8]. A prospective cohort study under the ‘‘Reference
Centre for Hereditary Immunodeficiency” aims to define new
diagnostic criteria [1]. All studies are retrospective and uncon-
trolled and low numbers do not allow consensual conclusion to
be drawn from [3]. However, the principle of the therapeutic
management of acquired HLH is based on three simultaneous
approaches. The first consists of support or intensive care mea-
sures. The second approach consists of determining the trigger
factor and eliminates it, the thing that may be enough to stop
the progression of the HLH [1]. Sixty to seventy-eight percent
is the survival rate of cases of HLH-tuberculosis put under
anti-bacillary treatment (alone or associated with a high dose
of corticosteroid therapy) versus 0% in the no treatment group
(diagnostic retained at autopsy) [5]. The third approach
involves the removal of the excessive inflammatory response.
The choice of drug depends on the underlying disease, severity
of symptoms, response to initial treatment and the episode of
the HLH [1,3]. However, immunosuppressant may worsen the
mycobacterial infection [9]. So the issue of the interest of corticos-
teroids, immunosuppressant and intravenous immunoglobulin in
combination with TB treatment is debated. Triglycerides,
serum ferritin, CRP and ESR can be useful for monitoring
the disease and the therapeutic activity [3]. The lack of
response after three weeks is often an indicator of a refractory
HLH, which is why some authors propose Cyclosporine then
Tacrolimus and Etoposide as last resort [3]. Relapse is not
uncommon. The prognosis is guarded with a mortality rate
of 49% [3,10]. It depends on the underlying disease, the speed
of care and treatment regimen [10]. If HLH is related to tuber-
culosis, the prognosis is unfortunate with a mortality rate of
50% [5]. Other poor prognostic factors, previously defined,
are age over 30 years, hyperferritinemia, disseminated
intravascular coagulation and high levels of beta-2-
microglobulin. The death of our patient may be explained by
the presence of several poor prognostic factors: age above
30 years, the very high rate of ferritin, diagnostic delay and
serious form of tuberculosis.Conclusion
The tuberculous is exceptional cause of secondary HLH. This
association is always a problem in therapeutic care in the
absence of international recommendations.References
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